FDA grants Fast Track Designation for the trial
The U.S. Food and Drug Administration has granted Fast Track Designation to the Phase II Non-Muscle Invasive Bladder Cancer clinical study, opening the possibility of an Accelerated Approval and Priority Review. More details can be found at the Theralase press release.